Oppenheimer Asset Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.57M | Buy |
72,703
+2,817
| +4% | +$196K | 0.05% | 344 |
|
|
2025
Q4 | $4.64M | Sell |
69,886
-17,765
| -20% | -$1.15M | 0.06% | 312 |
|
|
2025
Q3 | $5.9M | Sell |
87,651
-13,360
| -13% | -$1.06M | 0.06% | 311 |
|
|
2025
Q2 | $8.82M | Sell |
101,011
-869
| -0.9% | -$68.1K | 0.1% | 227 |
|
|
2025
Q1 | $6.96M | Buy |
101,880
+10,094
| +11% | +$824K | 0.09% | 255 |
|
|
2024
Q4 | $7.14M | Buy |
91,786
+11,871
| +15% | +$879K | 0.09% | 249 |
|
|
2024
Q3 | $5.36M | Sell |
79,915
-53,993
| -40% | -$4.43M | 0.06% | 308 |
|
|
2024
Q2 | $15.2M | Buy |
133,908
+17,443
| +15% | +$2.21M | 0.19% | 124 |
|
|
2024
Q1 | $16.2M | Sell |
116,465
-5,811
| -5% | -$730K | 0.24% | 99 |
|
|
2023
Q4 | $15.2M | Buy |
122,276
+33,580
| +38% | +$3.43M | 0.21% | 112 |
|
|
2023
Q3 | $8.28M | Sell |
88,696
-1,907
| -2% | -$215K | 0.13% | 193 |
|
|
2023
Q2 | $11.6M | Sell |
90,603
-839
| -0.9% | -$101K | 0.17% | 143 |
|
|
2023
Q1 | $10.6M | Sell |
91,442
-3,430
| -4% | -$384K | 0.16% | 156 |
|
|
2022
Q4 | $10.7M | Sell |
94,872
-2,139
| -2% | -$235K | 0.17% | 158 |
|
|
2022
Q3 | $7.81M | Sell |
97,011
-1,725
| -2% | -$146K | 0.14% | 185 |
|
|
2022
Q2 | $7.36M | Buy |
98,736
+804
| +0.8% | +$73.4K | 0.12% | 202 |
|
|
2022
Q1 | $12.5M | Buy |
97,932
+1,012
| +1% | +$111K | 0.18% | 138 |
|
|
2021
Q4 | $13M | Buy |
96,920
+2,228
| +2% | +$320K | 0.17% | 140 |
|
|
2021
Q3 | $12.9M | Buy |
94,692
+2,076
| +2% | +$262K | 0.18% | 131 |
|
|
2021
Q2 | $9.89M | Buy |
92,616
+15,064
| +19% | +$1.45M | 0.14% | 174 |
|
|
2021
Q1 | $6.97M | Buy |
77,552
+2,408
| +3% | +$226K | 0.11% | 218 |
|
|
2020
Q4 | $6.95M | Buy |
75,144
+844
| +1% | +$75.4K | 0.12% | 206 |
|
|
2020
Q3 | $7.66M | Buy |
74,300
+2,460
| +3% | +$257K | 0.15% | 166 |
|
|
2020
Q2 | $7.28M | Buy |
71,840
+600
| +0.8% | +$53.7K | 0.15% | 165 |
|
|
2020
Q1 | $4.79M | Buy |
71,240
+528
| +0.7% | +$32.9K | 0.12% | 203 |
|
|
2019
Q4 | $3.87M | Buy |
70,712
+1,404
| +2% | +$66.6K | 0.08% | 270 |
|
|
2019
Q3 | $2.58M | Buy |
69,308
+1,776
| +3% | +$69K | 0.06% | 339 |
|
|
2019
Q2 | $2.53M | Sell |
67,532
-932
| -1% | -$29.3K | 0.06% | 344 |
|
|
2019
Q1 | $2.04M | Buy |
68,464
+68,064
| +17,016% | +$2.39M | 0.05% | 398 |
|
|
2018
Q4 | $12K | Buy |
+400
| New | +$12.7K | ﹤0.01% | 1499 |
|
|
2018
Q1 | – | Sell |
-21,636
| Closed | -$265K | – | 1139 |
|
|
2017
Q4 | $265K | Hold |
21,636
| – | – | 0.01% | 968 |
|
|
2017
Q3 | $265K | Sell |
21,636
-76,740
| -78% | -$1.36M | 0.01% | 972 |
|
|
2017
Q2 | $1.8M | Sell |
98,376
-580
| -0.6% | -$10.7K | 0.05% | 388 |
|
|
2017
Q1 | $2.1M | Buy |
+98,956
| New | +$1.93M | 0.06% | 341 |
|
Other funds holding DXCM
VCM
VPM
Oppenheimer Asset Management's DXCM Position: Q1 2026 in Review
Oppenheimer Asset Management increased its DexCom (DXCM) stake by 4% in Q1 2026, buying an estimated $196K and bringing the position to 72,703 shares worth $4.57M. The position accounts for 0.05% of the portfolio, ranked #344.
Oppenheimer Asset Management first reported a position in DXCM in Q1 2017 and has held it in 34 quarters since. The position peaked at $16.2M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Oppenheimer Asset Management held 72,703 shares of DexCom worth $4.57M as of Q1 2026.
- Oppenheimer Asset Management bought 2,817 DexCom shares in Q1 2026, an estimated $196K.
- DexCom made up 0.05% of Oppenheimer Asset Management's portfolio in Q1 2026, its #344 holding.
- Oppenheimer Asset Management first reported a position in DexCom in Q1 2017 and has held it in 34 quarters since.
- Oppenheimer Asset Management's DexCom position peaked at $16.2M in Q1 2024.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.